Radiological Staging for Distant Metastases in Breast Cancer Patients with Confirmed Local and/or Locoregional Recurrence: How Useful are Current Guideline Recommendations?
- 161 Downloads
Breast cancer patients with local and/or locoregional recurrence (LR) are at higher risk of developing distant metastases (DM) at a later time. Once LR has been confirmed, some international interdisciplinary guidelines recommend performing radiological examinations for DM to determine the course of further therapy (curative or palliative approach). This study analyzed the metastatic patterns of patients with LR with particular regard to the frequency of concurrent diagnosis of LR and DM; in other words: are radiological staging procedures actually justified for DM at the time of diagnosis of LR?
This study included all patients (n = 1368) who were diagnosed and treated for nonmetastatic breast cancer (Stage I–III) at the University Women’s Hospital Basel, Switzerland between 1990 and 2009.
In 137 patients, LR was diagnosed without a history of DM: in-breast/thoracic wall only, n = 90 (65.7%); involvement of axillary/supra-/infraclavicular lymph nodes, n = 47 (34.3%). DM was found at the time of diagnosis of LR in 44 patients (32.1%). Concurrent diagnosis of LR and DM occurred significantly more often in patients with lymph node recurrence compared with those with in-breast/chest wall recurrence (48.9% vs. 23.3%; p = 0.004).
Approximately one-third of patients with a LR had synchronous DM at the time of their local/locoregional event. For this reason, routine systemic staging imaging at the time of LR should be an absolute requirement for planning further therapy. Confirmation of DM may spare the patients radical surgical interventions with questionable impact on survival in the face of an incurable disease.
The authors thank Serenella Eppenberger-Castori from the Institute for Pathology of the University Hospital of Basel for statistical analyses.
The authors declare that they have no conflicts of interest to disclose.
- 2.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRefGoogle Scholar
- 6.Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node negative breast cancer. J Clin Oncol. 2009;27:2466–73.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx. PDF version, page MS-53-55. Accessed 28 Oct 2018.
- 8.American Society of Clinical Oncology (ASCO). Quality and guidelines. Breast Cancer. Available at: https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/breast-cancer. Accessed 10 Dec 2018.
- 11.Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.0, 2017 AWMF Registernummer: 032-045OL. Available at: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/PDF version, page 198-201. Accessed 28 Oct 2018.
- 18.Neuman HB, Schumacher JR, Francescatti AB, The Alliance/American College of Surgeons Clinical Research Program Cancer Care Delivery Research Breast Cancer Surveillance Working Group, et al. Risk of synchronous distant recurrence at time of locoregional recurrence in patients with stage II and III breast cancer (AFT-01). J Clin Oncol. 2018;36:975–80.CrossRefPubMedPubMedCentralGoogle Scholar